Artiva Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (ARTV)

CUSIP: 04317A107

Q1 2025 13F Holders as of 31 Mar 2025

Holder snapshot 6 signals
Share change
-274,491
SEC-reported price per share
$3.00
Indexed holders
52
Value change
-$3,180,578
Number of buys
23
Number of sells
19
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
48,657,048

Security key

04317A107

Report period

Q1 2025

Indexed institutions

52

Top holders

10

Ownership snapshot

Top reported holders of ARTV - Artiva Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
venBio Global Strategic F...
Disclosed value leader
RA CAPITAL MANAGEMENT, L.P.
Comparable rows
1/15
Latest evidence
31 Mar 2025
13D/G 3/4/5 13F Lead comparable stake: 4.9% 14 rows are not safely comparable across share classes. 13D/G row: venBio Global Strategic Fund III, L.P. Showing 1-6 of 15 holder rows.

Quick read

venBio Global Strategic Fund III, L.P. leads the comparable SEC ownership view at 4.9%.

1 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens venBio Global Strategic Fund III, L.P.'s linked filing trail.
Comparable ownership Top 1
venBio Global Strategic Fund III,... 4.9%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
venBio Global Strategic Fund III, L.P.
13D/G 3/4/5
10%+ Owner
4.9%
Reported 13D/G · 31 Mar 2025
$2,937,489
1,198,975 shares
$0 31 Mar 2025
5AM Partners VI, LLC
3/4/5
10%+ Owner
—
denominator unverified
—
2,353,304 shares
— 22 Jul 2024
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.
3/4/5
10%+ Owner
—
denominator unverified
—
194,108 shares
— 22 Jul 2024
RA CAPITAL MANAGEMENT, L.P.
13F
Company
13F
—
denominator unverified
$99,321,284
9,853,302 shares
— 31 Dec 2024
5AM Venture Management, LLC
13F
Company
13F
—
denominator unverified
$23,721,304
2,353,304 shares
— 31 Dec 2024
Venrock Adviser, LLC
13F
Company
13F
—
denominator unverified
$16,224,456
1,609,569 shares
— 31 Dec 2024
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
52
Shares
20,919,533
Indexed holders
52
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q1 2025 vs Q4 2024 Across Filers

Q4 2024 indexed holders
57
Q1 2025 indexed holders
52
Indexed holder difference
-5
Investor Q4 2024 Shares Q1 2025 Shares Share Diff Share Chg % Q4 2024 value Q1 2025 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .